FDA 483 - CSL Plasma Inc - March 22, 2023

An FDA inspection of CSL Plasma, Inc. in Las Vegas, Nevada, revealed a critical deficiency in donor notification procedures. The firm failed to inform donors of reactive test results for relevant transfusion-transmitted infections, including positive HIV screening and confirmatory results, which led to donor deferral. This indicates a serious non-compliance with established protocols for unsuitable events management.